Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Verona Pharma Reports Bronchodilator Data with RPL554 in COPD Patients

Published: Tuesday, January 15, 2013
Last Updated: Tuesday, January 15, 2013
Bookmark and Share
Data was presented at the 2012 European Respiratory Society Annual Congress in Vienna.

Verona Pharma plc has announced the completion and reporting of data from a clinical trial with its lead drug candidate, the dual PDE 3 and 4 inhibitor RPL554, in patients with chronic obstructive pulmonary disease (COPD).

The data was presented by the trial’s Principal Investigator, Professor Mario Cazzola, at the European Respiratory Society (ERS) Annual Congress in Vienna.

The Phase II trial was a placebo-controlled cross-over study in 12 patients with mild to moderate COPD and was carried out at the Tor Vergata Clinic at the University of Rome, Italy.

The data showed that a single dose of nebulized RPL554 to patients with COPD produced a rapid bronchodilator response, greater than a 15% increase in FEV1 (forced expiratory volume at 1 second).

This magnitude of bronchodilator response was significantly larger than that produced by placebo and appeared to be at least equivalent to that produced by a standard dose of the reference bronchodilator beta2-agonist salbutamol in these patients.

In addition, inhalation of 0.018 mg/kg of RPL554 was well tolerated and did not cause any significant adverse effects.

Professor Cazzola commented: “Our results with RPL554 show that this is a promising novel class of bronchodilator drug for the treatment of asthma and COPD.”

This completes the first bronchodilator study in mild to moderate COPD patients at the Tor Vergata Clinic in Rome and is an expansion of the pilot part of the study announced by the Company on 10 November 2011.

Dr. Jan-Anders Karlsson, CEO of Verona Pharma said: “These data with RPL554 in COPD patients confirms the bronchodilator activity that we have previously observed in a smaller group of COPD patients and in asthmatics. RPL554 has a very interesting profile with its rapid onset of action. In addition to its bronchodilator activity, we are evaluating its potential anti-inflammatory effect in the clinical trial that is currently on-going at the Medicines Evaluation Unit in Manchester.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

US Patent Granted for Verona Pharma’s RPL554
Company is currently carrying out clinical trials of the drug, RPL554.
Tuesday, January 01, 2013
Verona Pharma Appoints New CEO
Appointment of experienced biotechnology CEO as part of succession planning.
Friday, May 04, 2012
Verona Pharma Appoints Manchester Clinical Research Facility to Carry Out Clinical Trial with RPL554
Enrollment of patients to start Q2, with results expected early Q4 2012.
Friday, March 09, 2012
Verona Pharma Successfully Completes £3.25 Million Placing
Placing to provide Company with sufficient working capital to finance RPL554 clinical trial programme.
Monday, December 12, 2011
Verona Pharma Announces Positive Results for RPL554 in Mild Asthma at Higher Doses
Verona has completed a successful trial in which 20 mild asthmatic subjects treated with either single doses of RPL554 or placebo administered via a nebulizer.
Wednesday, February 23, 2011
Verona Pharma Applies for Approval to Test RPL554 in UK Clinical Trials
RPL554 is Verona Pharma’s lead drug compound which is a long acting bronchodilator/anti-inflammatory drug belonging to a class of drugs known as a mixed PDE 3/4 inhibitor.
Monday, February 14, 2011
Scientific News
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Key to Natural Detoxifier’s Reactivity Discovered
Results have implications for health, drug design and chemical synthesis.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Michigan Researchers Use Raman Spectroscopy
inVia confocal Raman microscope used in the study of various childhood diseases.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos